Scilex Holding (SCLXW) Cash & Current Investments (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Cash & Current Investments of $145.1 million in Q1 2026, up 1200.52% quarter-over-quarter from $11.2 million in Q4 2025, and up 2401.26% on a YoY basis from $5.8 million in Q1 2025.
Scilex Holding (SCLXW) Cash & Current Investments (2020 - 2026) Analysis & Trends
Scilex Holding's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $145.1 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 2401.26% year-over-year to $145.1 million; the TTM figure through Mar 2026 stood at $145.1 million (up 2401.26% YoY), while the FY2025 annual figure was $11.2 million, up 240.92% from the prior year.
- Cash & Current Investments was $145.1 million for Q1 2026 at Scilex Holding, up from $11.2 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $145.1 million in Q1 2026 to a low of $69922.0 in Q3 2022.
- Historically, Cash & Current Investments has averaged $29.9 million across 5 years, with a median of $4.1 million in 2025.
- Biggest YoY gain for Cash & Current Investments was 55034.43% in 2022; the steepest drop was 98.48% in 2022.
- A 5-year view of Cash & Current Investments shows it stood at $2.2 million in 2022, then surged by 79.53% to $3.9 million in 2023, then dropped by 16.55% to $3.3 million in 2024, then surged by 240.92% to $11.2 million in 2025, then surged by 1200.52% to $145.1 million in 2026.
- The last three Cash & Current Investments figures came in at $145.1 million (Q1 2026), $11.2 million (Q4 2025), and $900000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.38 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 10.49 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | 145.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 145.07 Mn |
| Dec 31, 2025 | 11.16 Mn |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 4.10 Mn |
| Mar 31, 2025 | 5.80 Mn |
| Dec 31, 2024 | 3.27 Mn |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Dec 31, 2023 | 3.92 Mn |
| Sep 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 34.12 Mn |
| Mar 31, 2023 | 5.10 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 69,922.00 |
| Jun 30, 2022 | 142.04 Mn |
| Mar 31, 2022 | 140.58 Mn |
| Dec 31, 2021 | 143.75 Mn |
| Sep 30, 2021 | 115,642.00 |
| Jun 30, 2021 | 257,621.00 |